Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 59Stomach Neoplasms 12Colonic Neoplasms 9Rectal Neoplasms 5Triple Negative Breast Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Neoplasms 2Neoplasm Metastasis 2NSCLC 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Advanced Solid Tumors 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1MSS Metastatic Colorectal Cancer 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cisplatin 115Radiotherapy 83Paclitaxel 77Fluorouracil 61Carboplatin 41Drug Therapy 34pembrolizumab 33Irinotecan 33tislelizumab 27Docetaxel 26Oxaliplatin 23Neoadjuvant Therapy 23toripalimab 22sintilimab 19camrelizumab 19Radiation 19Esophagectomy 17Capecitabine 17130-nm albumin-bound paclitaxel 17Surgical Procedures, Operative 15Leucovorin 15Nivolumab 14Cetuximab 14TP protocol 12S 1 (combination) 12Radiotherapy, Intensity-Modulated 12Albumin-Bound Paclitaxel 12nimotuzumab 11apatinib 10anlotinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Esophageal Squamous Cell Carcinoma × HMPL-013 × Clear all
NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05636150 2022-12-05

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

Peking Union Medical College Hospital

Phase 2 Unknown
48 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡